- $77.01m
- $79.61m
- $35.59m
- 44
- 27
- 91
- 54
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 5.3 | ||
| Price to Tang. Book | 7.11 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2.23 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -38.37% | ||
| Return on Equity | -94.65% | ||
| Operating Margin | -45.6% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 41 | 43.17 | 34.69 | 31.08 | 35.59 | 41.14 | 49.48 | 7.37% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
CytoSorbents Corporation is engaged in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. The Company’s blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its lead product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses that can lead to massive inflammation, organ failure and patient death. Its products also include ECOS-300CY, VetResQ, DrugSorb-ATR, and PuriFi. DrugSorb-ATR is an investigational device that uses equivalent polymer technology to CytoSorb to address a large unmet need for blood thinner reversal in cardiothoracic surgery. ECOS-300CY is used to reduce cytokines and other inflammatory mediators when used in an ex vivo organ perfusion system.
Directors
- Al Kraus NEC (75)
- Vincent Capponi PRE (62)
- Phillip Chan CEO (49)
- Kathleen Bloch CFO (65)
- Efthymios Deliargyris CSO (52)
- Michael Bator IND (56)
- Edward Jones IND (71)
- Alan Sobel IND (59)
- Last Annual
- December 31st, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- October 28th, 2014
- Public Since
- June 17th, 2005
- No. of Shareholders
- 11,100
- No. of Employees
- 149
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 62,610,376
- Address
- 305 COLLEGE ROAD EAST, PRINCETON, 08540
- Web
- https://cytosorbents.com/
- Phone
- +1 9733298885
- Auditors
- Withum- Smith & Brown
Upcoming Events for CTSO
Q3 2025 Cytosorbents Corp Earnings Release
Similar to CTSO
Adagio Medical Holdings
NASDAQ Capital Market
Adapthealth
NASDAQ Capital Market
Aethlon Medical
NASDAQ Capital Market
Agape ATP
NASDAQ Capital Market
Alpha Tau Medical
NASDAQ Capital Market
FAQ
What is the Cytosorbents share price?
As of Today at 11:10 UTC, shares in Cytosorbents are trading at $1.23. This share price information is delayed by 15 minutes.
How has the Cytosorbents share price performed this year?
Shares in Cytosorbents last closed at $1.23 and the price had moved by +59.22% over the past 365 days. In terms of relative price strength the Cytosorbents share price has outperformed the S&P500 Index by +40.84% over the past year.
What are the analyst and broker recommendations for Cytosorbents?
The overall consensus recommendation for Cytosorbents is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Cytosorbents dividend yield?
Cytosorbents does not currently pay a dividend.
Does Cytosorbents pay a dividend?
Cytosorbents does not currently pay a dividend.
When does Cytosorbents next pay dividends?
Cytosorbents does not currently pay a dividend.
How do I buy Cytosorbents shares?
To buy shares in Cytosorbents you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Cytosorbents?
As of the previous close price of $1.23, shares in Cytosorbents had a market capitalisation of $77.01m.
Where are Cytosorbents shares listed?
Here are the trading details for Cytosorbents:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: CTSO
What kind of share is Cytosorbents?
Based on an overall assessment of its quality, value and momentum Cytosorbents is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Cytosorbents share price forecast for 2025?
The analyst consensus target price for shares in Cytosorbents is $5.00. That is 306.5% above the last closing price of $1.23.
Analysts covering Cytosorbents currently have a consensus Earnings Per Share (EPS) forecast of -$0.16 for the next financial year.
Find out moreWhat is the trend in the Cytosorbents share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cytosorbents. Over the past six months, its share price has outperformed the S&P500 Index by +25.22%.
As of the last closing price of $1.23, shares in Cytosorbents were trading +19.01% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Cytosorbents PE Ratio?
The Cytosorbents PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.23.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Cytosorbents?
Cytosorbents' management team is headed by:
- Al Kraus - NEC
- Vincent Capponi - PRE
- Phillip Chan - CEO
- Kathleen Bloch - CFO
- Efthymios Deliargyris - CSO
- Michael Bator - IND
- Edward Jones - IND
- Alan Sobel - IND